Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castrate Resistant Prostate Cancer (CRPC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01558492
What this trial is testing

Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 3
Testing effectiveness (Phase 2)Study completedNCT01284920
What this trial is testing

MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Who this might be right for
Prostate CancerProstate NeoplasmsCastration Resistant Prostate Cancer (CRPC)
Astellas Pharma Inc 47
Testing effectiveness (Phase 2)Study completedNCT03314324
What this trial is testing

Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Who this might be right for
Metastatic Castrate-resistant Prostate (CRPC) Cancer
Gustave Roussy, Cancer Campus, Grand Paris 250
Testing effectiveness (Phase 2)Study completedNCT02012296
What this trial is testing

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Who this might be right for
Hormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
University of Chicago 88
Testing effectiveness (Phase 2)WithdrawnNCT00811031
What this trial is testing

Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center
Early research (Phase 1)Ended earlyNCT03150056
What this trial is testing

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Who this might be right for
Solid Tumours
GlaxoSmithKline 73
Testing effectiveness (Phase 2)Ended earlyNCT01709734
What this trial is testing

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
LTN PHARMACEUTICALS, INC. 126
Testing effectiveness (Phase 2)Study completedNCT01046916
What this trial is testing

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 38
Early research (Phase 1)UnknownNCT02502994
What this trial is testing

Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC

Who this might be right for
Castration Resistant Prostate Cancer
Norio Nonomura 12
Testing effectiveness (Phase 2)Study completedNCT02288936
What this trial is testing

Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Spanish Oncology Genito-Urinary Group 98
Testing effectiveness (Phase 2)WithdrawnNCT02793765
What this trial is testing

Docetaxel Followed by Provenge in Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
The University of Texas Health Science Center, Houston
Testing effectiveness (Phase 2)Study completedNCT01511536
What this trial is testing

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Sanofi 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT05849298
What this trial is testing

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Who this might be right for
Prostatic Neoplasm
Novartis Pharmaceuticals 49
Testing effectiveness (Phase 2)UnknownNCT05579184
What this trial is testing

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2

Who this might be right for
Metastatic Castration-resistant Prostate Cancer, mCRPC
FutureChem 20
Early research (Phase 1)Study completedNCT03569280
What this trial is testing

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Who this might be right for
Castration-Resistant Prostate Cancer
Kangpu Biopharmaceuticals, Ltd. 16
Large-scale testing (Phase 3)Study completedNCT00988208
What this trial is testing

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Celgene 1,059
Not applicableStudy completedNCT03563014
What this trial is testing

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Bayer 164
Large-scale testing (Phase 3)Looking for participantsNCT07200830
What this trial is testing

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Who this might be right for
Metastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology 1,524
Testing effectiveness (Phase 2)UnknownNCT05458544
What this trial is testing

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
FutureChem 26
Testing effectiveness (Phase 2)Looking for participantsNCT06549465
What this trial is testing

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics 93
Next Page